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Cancer of unknown primary (CUP) is a well recognized clinical syndrome, accounting for 3–5%
of all malignancies. It is characterized as a disease with an early dissemination of metastases
without a primary detected site after extensive laboratory and clinical investigations. CUP is
divided into the favorable and unfavorable groups based on histopathological and clinical man-
ifestations. Adenocarcinoma of various differentiations is the commonest histopathological
subtype. Favorable groups are treated with local or systemic treatment and some of them are
enjoying long-term survival. On the contrary, unfavorable groups are treated with empirical
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Treatmentchemotherapy having usually a dismal prognosis. Gene-proﬁling microarray diagnosis has a
high diagnostic sensitivity, but its predictive or prognostic value remains uncertain.
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Introduction
CUP is a common disease with an incidence of 3–5% among
other epithelial tumors. Worldwide the overall age-standard-
ized incidence per 100.000 people per year is ranging between
4–19 cases. It is characterized as a metastatic cancer diagnosed
without the primary site, despite histopathological and radio-
logical laboratory investigations. The median age at diagnosis
is 60 years with a male predilection [1].
Today, the deﬁnition of CUP includes patients who present
with histologically-conﬁrmed metastatic cancer in whom a
detailed medical history, complete physical examination
including pelvic and rectal examination, full blood count and
biochemistry, urinalysis and stool occult blood testing, histo-
pathological review of biopsy material with the use of immu-
nohistochemistry, chest radiography, computed tomography
(CT) of the abdomen and pelvis and, in certain cases, mam-
mography and PET scan fail to identify the primary site [1].
Biology of CUP
CUP’s biology is poorly understood although several molecu-
lar or translational research studies are available. One hypoth-
esis postulates that CUP does not undergo type 1 progression
(from a premalignant lesion to malignant) but instead it fol-
lows a type 2 progression without forming a primary site. A
second hypothesis supports that CUP follows the parallel pro-
gression model, where metastases can arise early in the devel-
opment of a malignant process [2,3].
Several research data have shown that CUP rarely harbors
activating point mutations in either oncogenes or tumor sup-
pressor genes, has active angiogenesis in 50–80%, overexpress
various oncogenes in 10–30%, hypoxia-related proteins in
25%, epithelial–mesenchymal transition markers in 16% and
have activated intracellular signaling axes such as AKT or
MAPK in 20–35% [4–6] (Table 1). Very recently global micr-
oRNA proﬁling showed no signiﬁcant expression differences
with metastases of matched known primary tumors failing to
identify any speciﬁc ‘‘CUP signature’’ [7,8].
Clinicopathological subsets
CUP is associated with a short history of symptoms and signs,
has an early dissemination with an aggressive behavior in most
Table 1 Molecular events in CUP patients.
N patients Molecules Method Results Prognostic/predictive value
Oncogenes
420 HER-2 IHC Overexpression 10–35% None
50 HER-2 PCR No mutations –
201 EGFR IHC Overexpression 12–61% Superior survival/correlated with response to cisplatin
126 c-Kit IHC Overexpression 3–13% None
50 c-Kit PCR No mutations –
173 PDGFR IHC Expression 3% None
Overexpression 10–25% None
Tumor suppressor genes
157 p53 IHC Overexpression 48–53% None
46 p53 PCR Mutations 26% None
Angiogenesis/hypoxia
253 VEGF IHC Overexpression 26–83% None
197 CD34 IHC Density 56–59% None
80 TSP-1 IHC Overexpression 20% None
125 HIF 1a IHC Expression 20% Adverse prognostic factor
Tumor stroma
76 MMP-2 IHC Overexpression 49% None
76 MMP-9 IHC Overexpression 36% None
76 TIMP-1 IHC Overexpression 44% Adverse prognostic factor
100 E-Cadherin IHC Expression 79%
100 EMT-phenotype IHC Expression 8% Adverse prognostic factor
Molecular pathways
100 cMet IHC Expression 42% Adverse prognostic factor
100 pMAPK IHC Expression 54% Predictive for chemotherapy
100 Notch 3 IHC Expression 73% None
100 PTEN IHC Expression 50% None
pAKT IHC Expression 76% Prognostic for survival
pRPS6 IHC Expression 59% Prognostic for survival
p21 IHC Expression 60% Prognostic for survival
IHC: immunohistochemistry, MMP=metalloproteinase, TIMP-1: tissue inhibitor of metalloproteinase 1, EMT: epithelial mesenchymal
transition, HIF: hypoxia – inducible factors.
Table 2 Required investigations for searching the primary site.
Clinicopathological data
 Histologically conﬁrmed metastatic cancer
 Detailed medical history
 Complete physical (including pelvic and rectal) examination
 Histopathology review with speciﬁc immunohistochemical study
Work-up for all patients
 Full blood count
 Biochemistry
 Urinalysis
 Testing for occult blood in stools
 Chest radiography
 CT scan of thorax, abdomen, and pelvis
Work-up for selected patients only
 Mammography (for all women)
 Breast MRI
 Testicular ultrasonography
 PET or CT scan
 Concentrations of serum a-fetoprotein and b human chorionic gonadotropin
 Concentrations of serum prostate-speciﬁc antigen (for all men)
 Concentrations of serum cancer antigen 125 and carcinoma antigen 15–3
 Endoscopy
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Table 3 CUP subsets.
Favorable subsets
1. Women with adenocarcinoma involving axillary lymph nodes
2. Women with papillary adenocarcinoma of peritoneal cavity
3. Squamous cell carcinoma involving cervical lymph nodes
4. Poorly diﬀerentiated neuroendocrine carcinomas. Merkel cell
carcinoma of unknown primary (localized disease)
5. Adenocarcinoma with a colon-proﬁle (CK20+, CK7, CDX2+)
6. Men with blastic bone metastases and elevated PSA
(adenocarcinoma)
7. Isolated inguinal adenopathy (squamous carcinoma)
8. Patients with a single, small, potentially respectable tumor
Unfavorable subsets
1. Adenocarcinoma metastatic to the liver or other organs
2. Poorly diﬀerentiated carcinoma
3. Non-papillary malignant ascites (adenocarcinoma)
4. Multiple cerebral metastases (adeno or squamous Ca)
5. Multiple lung/pleural metastases (adenocarcinoma)
6. Multiple metastatic bone disease (adenocarcinoma)
7. Squamous-cell carcinoma of the abdominal cavity
378 N. Pavlidis et al.of the times (three or more organs are involved) and often car-
ries unpredictable metastatic patterns. Unpredictable meta-
static pattern at diagnosis refers to the differences in the
incidence of metastatic sites between known and unknown pri-
mary carcinomas i.e. pancreatic cancer presenting as CUP has
4-fold higher incidence to affect bones, and 30% incidence to
appear with lung metastases in contrast to the known natural
history of known primary pancreatic cancer.
To search the primary site a number of investigations are
required including clinical data, immunohistochemistry stud-
ies, blood tests, radiological techniques and endoscopic proce-
dures [1]. Table 2 indicates the necessary investigations that
should be performed in suspected CUP cases.
Since 2003 CUP is divided into two separated groups the
favorable (20%) and the unfavorable (80%) group [9]. Favor-Table 4 Immunohistochemistry tests for investigating C
Step one
AE1 or AE3 pan-cytokeratin
Common leukocyte antigen
S100; HMB-45
S100; vimentin
Step two
CK7 or CK20;PSA
PLAP; OCT4; AFP; human chorionic gonadotropin
Hepatocyte paraﬃn 1; canalicular pCEA, CD10, or CD13
RCC; CD10
TTF1; thyroglobulin
Chromogranin; synaptophysin; PGP9.5; CD56
CK5 or CK6; p63
Step three
PSA; PAP
TTF1
GCDFP-15; mammaglobin; ER
CDX2; CK20
CDX2 (intestinal epithelium); CK20; CK7
ER; CA-125; mesothelin, WT1able subsets are those entities that respond to local and/or sys-
temic treatments and have a longer survival. Table 3
demonstrates the classiﬁcation of CUP patients into various
clinicopathological subsets.
Woman with adenocarcinoma involving axillary nodes
This is a CUP subset in which the primary site is most often
hidden in the breasts. It has a presentation similar to breast
cancer of stage II (N2 or N3 disease), and it affects exclusively
women of a mean age of 52 years. The most frequent histology
is ductal adenocarcinoma. Forty percent have positive estro-
gen receptors. After undergoing mastectomy, almost 70% of
the patients have an occult breast primary identiﬁed [10].
Women with papillary adenocarcinoma of peritoneal cavity
This entity has also been called primary peritoneal carcinoma.
Clinical presentation includes pain, ascites, abdominal masses
or intestinal obstruction. Median age is 60 years. Histopathol-
ogy is always compatible with serous papillary adenocarcinoma
with or without psammoma bodies. Immunohistochemical
expression of MUC10, estrogen receptors, mesothelin, WT1
and KRT7 can be found. Serum CA 125 is very often raised.
In comparison with primary ovarian cancer, primary perito-
neal carcinoma affects older women, has more bulky disease
and has more overexpression of HER 2 oncogene and Ki67
[11].
Squamous cell carcinoma involving cervical nodes
It is more frequent in men (80%) with a median age of 60 years
and it constitutes 5% of all head and neck cancers. Clinical
presentation includes a painless and unilateral cervical mass,
most commonly affecting Level II lymph nodes (jugulodiga-
stric or upper nodes). Fine needle aspiration has a diagnosticUP.
Diagnosis
Carcinoma
Lymphoma
Melanoma
Sarcoma
Adenocarcinoma
Germ-cell tumor
Hepatocellular carcinoma
Renal cell carcinoma
Thyroid carcinoma
Neuroendocrine carcinoma
Squamous cell carcinoma
Prostate
Lung
Breast
Colon
Pancreas or biliary
Ovary
Table 5 Cytokeratins used in CUP.
Cytokeratins
Colon CK7/CK20+
Stomach CK7/CK20+; CK7+/CK20+
Biliary CK7+/CK20; CK7+/CK20+
Pancreas CK7+/CK20; CK7+/CK20+
Lung CK7+/CK20
Ovarian, non-mucinous CK7+/CK20
Ovarian, mucinous CK7/CK20+; CK7+/CK20+
Breast CK7+/CK20
Urothelial CK7+/CK20+
Endometrium CK7+/CK20
Prostate CK7/CK20
Renal CK7/CK20
Liver CK7/CK20
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follow. Radiology is very helpful with a sensitivity of CT-scan
in 22%, MRI in 36% and PET-scan up to 60% [12].
Poorly differentiated neuroendocrine carcinoma
It represents the 90% of CUP neuroendocrine tumors, the rest
being of well differentiated low grade histology. It affects
males (65%) of a median age of 65 years. Retroperitoneal,
mediastinal or peripheral lymph nodes are the most common
dominant sites (40%) following by liver (25%) and bones
(10–15%) [13].
Recently, neuroendocrine Merkel cell nodal carcinoma of
stage IIIB has been recognized as having also a long-term
survival [14].
Adenocarcinoma with a colon-proﬁle (CK20+, CK7, CDX2+)
Up to now less than 100 cases have been reported mostly in
women, with a median age of 57 years. Disease is extended
in the abdomen involving abdominal nodes in 51%, peritoneal
surfaces in 50%, liver in 30% and ascites in 27% [15,16].
Unfavorable subsets metastatic visceral or skeletal CUP
These are the most frequent subsets of CUP. They have a poor
prognosis with a short survival. The most common histological
types are adenocarcinomas of moderate to poorly differenti-
ated (64%), the rest been undifferentiated tumors. It involves
mainly the liver in 40–50% of the cases, followed by lymph
nodes (35%), lungs (31%), bones (28%) and the brain (15%)
[1,9].
Searching for the primary
Pathology and immunohistochemistry
Histopathology is one the most important avenue in the elab-
oration of CUP diagnosis. Immunohistochemistry with a wide
battery of staining (including cytokeratins), is of a great value
since it could differentiate between: (a) carcinoma, sarcoma or
lymphoma, (b) adenocarcinoma, germ-cell tumor, hepatocellu-
lar, renal, thyroid, neuroendocrine or squamous carcinomas aswell as (c) the primary site of an adenocarcinoma (lung, breast,
ovarian, prostate, colon, pancreas or biliary cancer) (Tables 4
and 5) [17].
Molecular diagnosis
During the last decade commercial tests of gene proﬁling
microarrays became available for the diagnosis of CUP.
Assays on cDNA or miRNA platforms gave accuracy rates
up to 93% in detecting the primary site and could probably
allow particular and speciﬁc therapeutic management in
CUP patients [18,19]. Whether this promising technology will
lead us to better patients’ outcome, it remains uncertain. A
number of clinical trials are still ongoing.
Radiology
Over the past 30 years CT scan, MRI and PET-scan added
substantially to the detection of primary site. CT scans pro-
vided a diagnostic accuracy of 55% (36–74%) mainly in pan-
creatic, colorectal and lung cancer, while MRI was found to
be very sensitive in detecting primary breast cancers in 70%
of cases [1].
Fluorodeoxyglucose (FDG) PET accuracy in CUP ranges
between 25% and 43%. The most common primary sites
detected by PET are lung cancer (33%), head and neck cancers
(27%), followed by pancreatic, breast and colon cancers (4–
5%). 68Ga-DOTA-NOC receptor PET/CT is also very accu-
rate in identifying primary neuroendocrine tumors or their
metastatic lesions [20,21].
Endoscopy
Endoscopies in general, carry low accuracy rates and low sen-
sitivity and speciﬁcity. Endoscopies should not be used in all
CUP patients for the detection of primary site, unless they
are clinically presenting with relevant symptoms and signs or
in patients with speciﬁc histopathological ﬁndings. A colonos-
copy should be requested in CK7+, CK20+ and CDX2+ cases
or bronchoscopy in CK7+ and TTF1+ patients [1].
Serum tumor markers
Elevated epithelial serum tumor markers can be overexpressed
in CUP patients. In almost 70% of them two or three markers
can be concomitantly increased in a non-speciﬁc way. CA-125,
CA-15-3, CA19-9, CEA can be raised without any diagnostic,
prognostic or predictive value. Therefore, routine request of
these tumor markers is not recommended. However, in speciﬁc
cases it might offer diagnostic aid such as serum prostate-spe-
ciﬁc antigen in men with osteoblastic bone metastases, CA125
in females with primary serous papillary peritoneal adenocar-
cinoma, or CA 15-3 in women with isolated axillary adenocar-
cinoma [22].Molecular diagnosis
During the last ten years gene-expression proﬁling in the clas-
siﬁcation and detection of primary tumor sites has led to the
development of commercially available tests. The accuracy
Fig. 1 Overall survival between CUP favorable and unfavorable
patients treated at Ioannina University Hospital from 1995 to
2011. Favorable ( ) and unfavorable ( ).
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tice remains uncertain. Randomized prospective studies are
needed to establish whether patients’ outcomes are improved
by its clinical use.Table 6 Therapy of patients with CUP according to ESMO guidel
CUP subsets Recommen
Poorly diﬀerentiated neuroendocrine carcinoma Platinum+
Serous papillary peritoneal adenocarcinoma Optimal su
Isolated axillary nodal metastases Axillary no
chemohorm
Squamous carcinoma involving cervical lymph nodes Neck dissec
For advanc
or chemora
Adenocarcinoma with a colon-proﬁle Chemother
Men with blastic bone metastases and IHC/serum
PSA expression
Androgen d
Single metastatic deposit from unknown primary Resection a
Unfavorable subsets Platinum-b
Table 7 Prognosis of favorable CUP patients.
CUP subset
Women with adenocarcinoma
involving axillary nodes
Women with papillary
adenocarcinoma of peritoneal cavity
Squamous cell carcinoma involving
cervical nodes
Poorly diﬀerentiated neuroendocrine
carcinoma
Adenocarcinoma with a colon cancer
proﬁleIt should be added here, that the frequency of detecting the
primary site by all conventional investigations antemortem is
around 30% (excluding gene proﬁling techniques) whereas
from the postmortem studies the detection could be up to
70% [9].
Therapeutic management (Table 6)
Women with adenocarcinoma involving axillary nodes
These patients should be treated with complete axillary dissec-
tion, ipsilateral breast radiotherapy followed by adjuvant che-
motherapy and/or hormonotherapy depending on the risk
factors. Patients without local treatment are associated with
high locoregional relapse rates (40–55%). Survival is longer
in patients who received primary breast radiotherapy as well
as in patients with adjuvant systemic treatment [1,10].
Women with papillary adenocarcinoma of peritoneal cavity
Patients with primary peritoneal adenocarcinoma should be
treated similarly to stage III and IV ovarian cancer. Surgical
cytoreduction followed by platinum and paclitaxel chemother-
apy is the treatment of choice. Median response rate is 80%
with 30–40% complete responders and a median survival of
36 months. Some reports have demonstrated poorer survival
of patients with primary peritoneal carcinoma as compared
to primary ovarian cancer due to reasons depicted in the sec-
tion of clinicopathological entities [1,11].ines.
ded treatment
etoposide combination chemotherapy
rgical debulking followed by platinum–taxane-based chemotherapy
dal dissection, mastectomy or breast irradiation and adjuvant
onotherapy
tion and/or irradiation of bilateral neck and head-neck axis.
ed stages induction chemotherapy with platinum-based combination
diation
apy regimens for colorectal cancer
eprivation therapy ± RT
nd/or RT ± systemic therapy
ased empirical chemotherapy
Survival
Mean 5-year overall survival: 72%
Mean overall survival : 36 months (2–6 months less
than primary ovarian cancer)
5-year survival: 60–65%
Median survival: 15.5 months with 2-yr survival: 33–
50%. Long-term survivors : 10–15%
Median overall survival: 20–36 months
Table 8 Algorithm in searching and treating the primary site.
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Patients with N1 or N2a disease without extra capsular exten-
sion could be treated with surgery alone including excisional
biopsy, radical or modiﬁed radical neck dissection, and/or
bilateral tonsillectomy. Locoregional control is around 80–
90% and 5-year overall survival up to 65%. Postoperative
radiotherapy is indicated in excisional or incisional biopsy,
extracapsular extension, stage N2b or higher, in ﬁxed nodes
to the adjacent structure or in patients with low performance
status and comorbidities. The irradiation ﬁelds include the
involved nodal stations (65–70 Gy), the uninvolved sites
(50 Gy) and the mucosal sites (50–60 Gy).
Chemoradiation could be indicated in N2 or N3 cases with
cisplatin based chemotherapy. Chemoradiation could be asso-
ciated with signiﬁcant grade 3 toxicities [1,12].
Poorly differentiated neuroendocrine carcinomas
This group of patients should be treated with platinum-based
or platinum–taxane combination chemotherapy. Response
rates are up to 55% with 20% complete responders and overall
survival of 15 months and almost 10–15% long-term survivors
[1,13].
Adenocarcinoma with a colon-proﬁle (CK20+, CK7, CDX2+)
This subset of patients should be treated as advanced colorec-
tal cancer cases. Overall response rate is 50% with 15%
complete and 35% partial responses and median survival of
21–37 months [1,15,16].Other favorable subsets
Patients with metastatic bone metastases and elevated serum
PSA should be managed as advanced prostate cancer [1].
Patients with isolated inguinal nodal metastases or a single
metastatic lesion should undergo local dissection with or with-
out local radiotherapy [1].
Treatment of unfavorable subsets
Unfortunately, this group of CUP patients represents the 80%
of the cases. They are usually treated with empirical chemo-
therapy mostly with platinum or taxane combinations.
Response rates are around 20% and median survival of six
months (Fig. 1). A recent meta-analysis has shown that no type
of chemotherapy has demonstrated any survival beneﬁt in
these subsets [23,24]. Speciﬁc targeted treatment in CUP
patients following gene proﬁling microarray tests has not yet
been proven. Since there are no prospective randomized
studies available, we have to wait until some already ongoing
trials appear. Table 6 summarizes therapeutic options accord-
ing to the ESMO guidelines [25] and Table 7 the prognostic
features of favorable subsets. Finally, Table 8 provides an
algorithm of searching the primary site and treating CUP
patients accordingly.
Conclusions
CUP is a well recognized clinical syndrome and may be deﬁned
as a disease with early disease dissemination without a primary
detected site. It could have a favorable or unfavorable out-
382 N. Pavlidis et al.come. Adenocarcinoma is the commonest histopathological
subtype. While favorable groups are treated with local or sys-
temic treatment, unfavorable groups are treated with empirical
chemotherapy having usually a dismal prognosis. The value of
gene-proﬁling microarray diagnosis though sensitive, its pre-
dictive or prognostic impact remains elusive.
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